A top-20 pharma improved the thermostability of a S. aureus vaccine antigen in a single Cradle round.
Rational design would have needed about seven rounds over 3.5-7 months for a 2.5 C melting temperature gain. Scientists ran one zero-shot round of 96 candidates with Cradle. The page reports a +2.50 C increase in melting temperature, 7x faster than rational design, with several variants between +1.5 C and +2.5 C.
Cradle is an AI protein engineering software company whose platform designs and optimizes proteins, antibodies, enzymes and peptides for biopharma and industry.
This sits in the Design & Stress-Test stage of the AI use-case lifecycle: Named examples from the tools pharma teams use to scope, prototype and benchmark an AI use case before committing to build it — data-catalog, sandbox and evaluation platforms.
Published by Cradle on its own site — read the original case study on cradle.bio ↗
Related use cases
- 01The Keasling Lab used Cradle to re-engineer plant enzymes for fermentation-based QS-21 vaccine adjuvant production.
- 02A top-20 pharma optimized three stalled late-stage peptide programs with Cradle in one round each.
- 03A top-50 pharma delivered 10 IgG candidates meeting potency and developability criteria after earlier campaigns failed.
- 04A biomanufacturing company nearly tripled P450 enzyme activity in three Cradle rounds after plateauing.
- 05Novo Nordisk Transforms Clinical Trials With AI
- 06How Regeneron is discovering new treatments with AI